In the phase 2b GENESIS study, bermekimab, an anti-IL-1α agent, was inferior to dupilumab in atopic dermatitis (AD), with only 16.7% of patients in both 350 mg and 700 mg bermekimab groups achieving EASI-75 at week 16, compared to 51.2% for dupilumab. This evidence concerns the gene IL1A and atopic eczema.